Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1Acromegaly 1

Interventions

Zoledronic Acid 14Leuprolide 9bicalutamide 6Triptorelin Pamoate 6Goserelin 6luprolide acetate gel depot 5enzalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Dutasteride 5fluciclovine F-18 3darolutamide 3Sodium Chloride 3Prednisone 3Magnetic Resonance Spectroscopy 3Flutamide 3Androgen Antagonists 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3cabazitaxel 2Propofol 2Prednisolone 2Lidocaine 2Gonadotropin-Releasing Hormone 2Finasteride 2Dexamethasone 2Desflurane 2Ciprofloxacin 2testosterone 17 beta-cypionate 1semaglutide 1polyethylene glycol 3350 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Prostatic Neoplasms × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡